MCID: MNT001
MIFTS: 76

Mantle Cell Lymphoma

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Mantle Cell Lymphoma

MalaCards integrated aliases for Mantle Cell Lymphoma:

Name: Mantle Cell Lymphoma 37 12 72 49 55 36 28 14
Lymphoma, Mantle Cell 49 13
Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse 69
Malignant Lymphoma - Lymphocytic, Intermediate Differentiation 69
Lymphoma, Mantle-Cell 41
Mantle Zone Lymphoma 55
Lymphoma Mantle-Cell 51
Mcl 55
Lcm 55

Characteristics:

Orphanet epidemiological data:

55
mantle cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (United States),1-9/100000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050746
MeSH 41 D020522
Orphanet 55 ORPHA52416
MESH via Orphanet 42 D020522
UMLS via Orphanet 70 C0555202
ICD10 via Orphanet 33 C83.1
KEGG 36 H01464
ICD10 32 C83.1

Summaries for Mantle Cell Lymphoma

NIH Rare Diseases : 49 Mantle cell lymphoma (MCL) belongs to a group of diseases known as non-Hodgkin’s lymphomas (NHL). NHL's are cancers that affect the the lymphatic system (part of the immune system). In MCL, there are cancerous B-cells (a type of immune system cell). The cancerous B-cells are within a region of the lymph node known as the mantle zone. Although MCLs are slow-growing cancers, the cancer is usually widespread by the time it is diagnosed. In these situations, treatment must be intensive since MCL can become life threatening within a short period of time. MCL accounts for 6% of all NHL's and is mostly found in males during their early 60s. Last updated: 4/27/2016

MalaCards based summary : Mantle Cell Lymphoma, also known as lymphoma, mantle cell, is related to lymphoma and follicular lymphoma, and has symptoms including splenomegaly, weight loss and anorexia. An important gene associated with Mantle Cell Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Imbruvica and Revlimid have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Increased cell death HMECs cells and Increased viability with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.

Wikipedia : 72 Mantle cell lymphoma (MCL) is a type of non-Hodgkin\'s lymphoma (NHL), comprising about 6% of NHL cases.... more...

Related Diseases for Mantle Cell Lymphoma

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 203)
# Related Disease Score Top Affiliating Genes
1 lymphoma 32.2 ATM BCL2 BCL6 CCND1 EZH2 MYC
2 follicular lymphoma 31.9 BCL2 BCL6 CCND1 CCND3 CD5 IGH
3 composite lymphoma 30.7 BCL6 CD5 SOX11
4 prolymphocytic leukemia 30.5 ATM CCND1 CD19 CD5 MYC
5 marginal zone b-cell lymphoma 30.5 BCL2 BCL6 CCND1 CD5 MME
6 b-cell lymphomas 30.4 BCL2 BCL6 CCND1 CCND2 CCND3 CD5
7 follicular lymphoma 1 30.3 BCL2 BCL6 IGH
8 myeloma, multiple 30.3 CCND1 CCND2 CCND3 CD19 MCL1 MYC
9 retinoblastoma 30.3 CCND1 CCND3 MDM2 TP53
10 b cell prolymphocytic leukemia 30.3 CD19 CD5 MYC TP53
11 diffuse large b-cell lymphoma 30.2 BCL6 CCND1 CD5 EZH2 MDM2 MME
12 lymphoma, mucosa-associated lymphoid type 30.1 BCL2 BCL6 CCND1 CD5 IGH MME
13 lymphoblastic lymphoma 30.1 BCL6 CD5 MME
14 cll/sll 30.1 ATM CCND1 CD5 MME SOX11 TP53
15 bladder cancer 30.0 CCND1 EZH2 MDM2 MYC TP53
16 leukemia, chronic lymphocytic 30.0 ATM BCL2 BCL6 CCND1 CCND2 CCND3
17 prostate cancer 29.7 BCL2 CCND1 EZH2 MCL1 MDM2 MTOR
18 colorectal cancer 29.4 ATM BCL2 CCND1 CCND2 MCL1 MDM2
19 lymphoma, non-hodgkin, familial 29.4 ATM BCL2 BCL6 CCND1 CCND2 CCND3
20 leukemia, acute myeloid 29.3 CD19 CD5 EZH2 MCL1 MDM2 MME
21 lymphoma, small cleaved-cell, diffuse 10.7 BCL2 CCND1
22 diffuse large b-cell lymphoma of the central nervous system 10.7 BCL2 MYC
23 ring chromosome 7 10.7 MDM2 TP53
24 synchronous bilateral breast carcinoma 10.7 ATM CCND1 TP53
25 hidradenocarcinoma 10.7 BCL2 CCND1 TP53
26 keratocystic odontogenic tumor 10.7 BCL2 CCND1 TP53
27 ectopic thymus 10.7 BCL2 CD5
28 actinic cheilitis 10.6 MDM2 TP53
29 hemimegalencephaly 10.6 CCND1 MTOR MYC
30 suppressor of tumorigenicity 3 10.6 BCL2 MYC TP53
31 pancreatic neuroendocrine tumor 10.6 ATM MTOR
32 myxosarcoma 10.6 ATM MDM2 TP53
33 focal cortical dysplasia, type ii 10.6 BCL2 MTOR TP53
34 soft tissue sarcoma 10.6 BCL2 MDM2 TP53
35 splenic diffuse red pulp small b-cell lymphoma 10.6 CCND3 TP53
36 estrogen-receptor positive breast cancer 10.6 CCND1 MTOR TP53
37 bile duct carcinoma 10.6 CCND1 MYC TP53
38 tracheal lymphoma 10.6 CD5 MME
39 male reproductive organ cancer 10.6 CCND1 MYC TP53
40 inflammatory myofibroblastic tumor 10.6 CCND1 MDM2 TP53
41 female reproductive organ cancer 10.6 CCND1 MYC TP53
42 richter's syndrome 10.6 ATM CD5 MYC TP53
43 li-fraumeni syndrome 10.6 ATM BCL2 MDM2 TP53
44 tongue cancer 10.6 BMI1 CCND1 TP53
45 cervical carcinosarcoma 10.6 BCL2 MME TP53
46 nodal marginal zone b-cell lymphoma 10.6 BCL2 BCL6
47 adult t-cell leukemia 10.5 CCND2 PMAIP1 TP53
48 oral squamous cell carcinoma 10.5 CCND1 MDM2 MYC TP53
49 dendritic cell thymoma 10.5 BCL2 CD5
50 reproductive organ cancer 10.5 CCND1 MYC TP53

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:



Diseases related to Mantle Cell Lymphoma

Symptoms & Phenotypes for Mantle Cell Lymphoma

Human phenotypes related to Mantle Cell Lymphoma:

55 31 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 55 31 frequent (33%) Frequent (79-30%) HP:0001744
2 weight loss 55 31 frequent (33%) Frequent (79-30%) HP:0001824
3 anorexia 55 31 frequent (33%) Frequent (79-30%) HP:0002039
4 lymphadenopathy 55 31 hallmark (90%) Very frequent (99-80%) HP:0002716
5 abnormality of bone marrow cell morphology 55 31 frequent (33%) Frequent (79-30%) HP:0005561
6 abnormality of the gastrointestinal tract 55 31 occasional (7.5%) Occasional (29-5%) HP:0011024
7 fatigue 55 31 frequent (33%) Frequent (79-30%) HP:0012378
8 fever 55 31 frequent (33%) Frequent (79-30%) HP:0001945
9 b-cell lymphoma 55 31 hallmark (90%) Very frequent (99-80%) HP:0012191

GenomeRNAi Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.63 BCL6 BMI1 CCND2 MDM2 MYC TP53
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 ATM BCL2 MCL1 MDM2 PMAIP1 TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 ATM BCL2 MCL1 TP53
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 ATM BCL2 BTK CCND1 MCL1 MYC

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

43 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 CD19 CCND2 CD5 CCND3 EZH2 BCL2
2 cardiovascular system MP:0005385 10.37 CCND3 EZH2 CD19 CCND2 BCL2 CCND1
3 cellular MP:0005384 10.36 CCND1 CD19 BTK BCL2 BCL6 ATM
4 immune system MP:0005387 10.36 CD19 CCND2 CD5 CCND3 EZH2 BCL2
5 homeostasis/metabolism MP:0005376 10.33 CCND3 EZH2 CCND1 CD19 CCND2 BTK
6 endocrine/exocrine gland MP:0005379 10.32 EZH2 CCND2 CCND3 BCL2 CCND1 BCL6
7 behavior/neurological MP:0005386 10.31 CCND3 CCND1 CD19 CCND2 BCL2 ATM
8 growth/size/body region MP:0005378 10.31 CCND3 CCND1 CD19 BTK BCL2 BCL6
9 integument MP:0010771 10.22 CD19 CD5 EZH2 BTK BCL2 CCND1
10 mortality/aging MP:0010768 10.2 CCND3 CCND1 CD19 CCND2 BTK BCL2
11 embryo MP:0005380 10.18 BCL2 ATM MTOR MDM2 EZH2 MCL1
12 digestive/alimentary MP:0005381 10.14 CCND1 CD19 BTK BCL2 MDM2 SOX11
13 liver/biliary system MP:0005370 9.97 CCND3 CD19 CCND2 BCL6 MDM2 MME
14 neoplasm MP:0002006 9.96 EZH2 CD19 CCND3 BTK BCL2 CCND1
15 nervous system MP:0003631 9.93 CCND1 CD19 CCND2 CD5 BCL2 ATM
16 normal MP:0002873 9.73 CCND3 EZH2 CD19 CD5 CCND1 BCL6
17 reproductive system MP:0005389 9.28 CCND1 CCND2 BCL2 BCL6 ATM MCL1

Drugs & Therapeutics for Mantle Cell Lymphoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Imbruvica 17 45 IBRUTINIB Pharmacyclics November of 2013/February 2014
2
Revlimid 17 45 LENALIDOMIDE Celgene June 2013
3
Velcade 17 45 BORTEZOMIB Millennium Pharmaceuticals May 2003

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 497)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
3 Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 52-24-4 5453
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
5
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 50-02-2 5743
7
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 23214-92-8 31703
8
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
10
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
11
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
12
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 159351-69-6 6442177
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
14
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 53123-88-9 46835353 6436030 5284616
15
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 31703
16 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
18 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
21 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2
22 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
23 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antiemetics Phase 4,Phase 3,Phase 1,Phase 2
25 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
26 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
27 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
28 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
29 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
31 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
33 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2
34 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
35 Dexamethasone acetate Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 1177-87-3
36 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
38 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
39 HIV Protease Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
40 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
41 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
44
protease inhibitors Phase 4,Phase 3,Phase 1,Phase 2
45 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
48
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 460612 4053
49
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
50
Vidarabine Approved, Investigational Phase 3,Phase 1,Phase 2 24356-66-9 21704 32326

Interventional clinical trials:

(show top 50) (show all 956)

# Name Status NCT ID Phase Drugs
1 An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Completed NCT01833039 Phase 4 Ibrutinib
2 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 EDOCH Alternating With DHAP for New Diagnosed Younger MCL Recruiting NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
4 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Active, not recruiting NCT01180049 Phase 4 temsirolimus;temsirolimus
5 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Not yet recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
6 Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma Unknown status NCT00016887 Phase 3 carmustine;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan
7 Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma Unknown status NCT00641095 Phase 3 cyclophosphamide;fludarabine phosphate
8 Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL Unknown status NCT00209222 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Cisplatinum;Ara-C;Dexamethasone;BCNU;Melphalan;Etoposide;G-CSF
9 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
10 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
11 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
12 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
13 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
14 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
15 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
16 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
17 Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
18 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
19 Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Completed NCT01646021 Phase 3 Ibrutinib;Temsirolimus
20 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma Completed NCT00722137 Phase 3 Rituximab 375 mg/m^2;Cyclophosphamide 750 mg/m^2;Doxorubicin 50 mg/m^2;VELCADE 1.3 mg/m^2;Prednisone 100 mg/m^2;Vincristine 1.4 mg/m^2
21 Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study Completed NCT00877006 Phase 3 bendamustine;rituximab;vincristine;prednisone;cyclophosphamide;doxorubicin
22 Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed NCT01073163 Phase 3 Bendamustine;Rituximab
23 Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma Completed NCT00003280 Phase 3
24 Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL) Completed NCT00117598 Phase 3 Temsirolimus (CCI-779);Temsirolimus (CCI-779);Investigator's choice
25 Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab Completed NCT01456351 Phase 3 Bendamustine plus Rituximab;Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
26 Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Completed NCT00921414 Phase 3 Rituximab
27 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3 Bendamustine;Standard chemotherapy CHOP + Ritiximab
28 A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma Completed NCT00269113 Phase 3 rituximab [MabThera/Rituxan];Standard chemotherapy
29 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
30 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
31 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
32 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
33 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
34 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
35 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
36 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
37 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
38 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
39 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
40 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
41 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
42 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
43 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
44 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
45 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
46 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
47 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
48 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
49 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
50 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin

Search NIH Clinical Center for Mantle Cell Lymphoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, mantle-cell

Genetic Tests for Mantle Cell Lymphoma

Genetic tests related to Mantle Cell Lymphoma:

# Genetic test Affiliating Genes
1 Mantle Cell Lymphoma 28

Anatomical Context for Mantle Cell Lymphoma

MalaCards organs/tissues related to Mantle Cell Lymphoma:

38
B Cells, Bone, Bone Marrow, T Cells, Liver, Kidney, Lymph Node

Publications for Mantle Cell Lymphoma

Articles related to Mantle Cell Lymphoma:

(show top 50) (show all 1070)
# Title Authors Year
1
Can we improve on ibrutinib in mantle cell lymphoma? ( 29396093 )
2018
2
Gastrointestinal involvement by mantle cell lymphoma identified by biopsy performed during endoscopy: A case report. ( 29419676 )
2018
3
Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. ( 29449436 )
2018
4
Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant? ( 29415598 )
2018
5
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. ( 29396091 )
2018
6
Population-based study of mantle cell lymphoma: Improvements in survival only seen in younger patients. ( 29363157 )
2018
7
CD40L mediated alternative NFI_B-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. ( 29367645 )
2018
8
Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma. ( 29392403 )
2018
9
Mantle Cell Lymphoma with a Single Protruding Lesion as the Cause of Intussusception. ( 29434133 )
2018
10
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. ( 29390098 )
2018
11
Commentary on: Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries. ( 29380057 )
2018
12
Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report. ( 29385883 )
2018
13
Rac1 is a novel therapeutic target in mantle cell lymphoma. ( 29434202 )
2018
14
Current trials for frontline therapy of mantle cell lymphoma. ( 29374487 )
2018
15
Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma. ( 29383700 )
2018
16
Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines. ( 29441438 )
2018
17
Wogonin Inhibits Growth of Mantle Cell Lymphoma Cells through Nuclear Factor-I_B Signaling Pathway. ( 29451160 )
2018
18
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. ( 28408615 )
2017
19
Correction: ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy. ( 28373366 )
2017
20
Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma. ( 28860327 )
2017
21
Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. ( 28404221 )
2017
22
Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma. ( 29043141 )
2017
23
Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients. ( 27776009 )
2017
24
Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications. ( 28115200 )
2017
25
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. ( 28040733 )
2017
26
Sudden Flank Pain in a Patient Receiving Ibrutinib for Mantle Cell Lymphoma. ( 28910460 )
2017
27
Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase 2 clinical trial of the Fondazione Italiana Linfomi. ( 28082342 )
2017
28
Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission. ( 28828884 )
2017
29
SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity. ( 28457728 )
2017
30
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. ( 28416797 )
2017
31
"Double trouble" - synchronous mantle cell lymphoma and metastatic squamous cell carcinoma in an inguinal lymph node. ( 29363922 )
2017
32
The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma. ( 28905990 )
2017
33
Mantle Cell Lymphoma in the Thyroid: A Rare Presentation. ( 29435379 )
2017
34
Case Study: Rare Case of Mantle Cell Lymphoma With Extranodal Involvement in the Foot. ( 28842094 )
2017
35
The drive to generate multiple forms of oncogenic cyclin D1 transcripts in mantle cell lymphoma. ( 28503306 )
2017
36
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. ( 28066928 )
2017
37
Gastrointestinal mantle cell lymphoma with isolated mass and multiple lymphomatous polyposis: report of two cases. ( 28451951 )
2017
38
SOX11 regulates the pro-apoptosis signal pathway and predicts a favorable prognosis of mantle cell lymphoma. ( 28429312 )
2017
39
Orbital mantle cell lymphoma presenting as myasthenia gravis. ( 28820310 )
2017
40
Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia. ( 28592433 )
2017
41
Mantle cell lymphoma with central nervous system involvement simulating bilateral subdural hematomas. ( 28063897 )
2017
42
Mantle Cell Lymphoma Presenting as a Subcutaneous Soft Tissue Mass With an Unusual Appearance. ( 28081018 )
2017
43
Expression of LEF1 in mantle cell lymphoma. ( 28038713 )
2017
44
Anchimerically Activated ProTides as Inhibitors of Cap-Dependent Translation and Inducers of Chemosensitization in Mantle Cell Lymphoma. ( 28858511 )
2017
45
The interaction between ATRIP and MCM complex is essential for ATRIP chromatin loading and its phosphorylation in mantle cell lymphoma cells. ( 29442041 )
2017
46
Maintenance Rituximab after High-Dose Therapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma. ( 28939452 )
2017
47
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. ( 28953447 )
2017
48
Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis. ( 28529032 )
2017
49
The BTK inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on the NF-I_B mutational status. ( 28838994 )
2017
50
A possible new morphological variant of mantle cell lymphoma with plasma-cell type Castleman disease-like features. ( 28974340 )
2017

Variations for Mantle Cell Lymphoma

ClinVar genetic disease variations for Mantle Cell Lymphoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ATM NM_000051.3(ATM): c.7251_7253dupGAA (p.Lys2418_Arg2419insLys) duplication Pathogenic rs796051857 GRCh38 Chromosome 11, 108329182: 108329184
2 ATM NM_000051.3(ATM): c.7268A> G (p.Glu2423Gly) single nucleotide variant Pathogenic rs121434221 GRCh37 Chromosome 11, 108199926: 108199926
3 ATM NM_000051.3(ATM): c.4081C> T (p.Gln1361Ter) single nucleotide variant Pathogenic rs121434222 GRCh37 Chromosome 11, 108158414: 108158414

Cosmic variations for Mantle Cell Lymphoma:

9 (show top 50) (show all 319)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM3733325 ZNF296 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.488G>A p.G163D 7
2 COSM3733324 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.6190G>A p.E2064K 7
3 COSM3733267 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.8147C>G p.S2716* 7
4 COSM6901 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.559+1G>A p.? 7
5 COSM44687 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.379T>C p.S127P 7
6 COSM44972 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.831T>A p.C277* 7
7 COSM43846 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.487T>C p.Y163H 7
8 COSM10786 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.949C>T p.Q317* 7
9 COSM10883 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.731G>A p.G244D 7
10 COSM11114 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.528C>G p.C176W 7
11 COSM10662 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.743G>A p.R248Q 7
12 COSM11450 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.644G>T p.S215I 7
13 COSM10758 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.659A>G p.Y220C 7
14 COSM44309 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.440T>G p.V147G 7
15 COSM10749 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.830G>T p.C277F 7
16 COSM10659 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.817C>T p.R273C 7
17 COSM43651 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.763A>T p.I255F 7
18 COSM43826 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.706T>A p.Y236N 7
19 COSM43814 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.587G>C p.R196P 7
20 COSM10724 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.839G>C p.R280T 7
21 COSM10648 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.524G>A p.R175H 7
22 COSM10705 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.586C>T p.R196* 7
23 COSM44467 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.497C>G p.S166* 7
24 COSM11089 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.584T>C p.I195T 7
25 COSM10656 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.742C>T p.R248W 7
26 COSM44962 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.774A>T p.E258D 7
27 COSM11123 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.838A>G p.R280G 7
28 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.581T>G p.L194R 7
29 COSM10660 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.818G>A p.R273H 7
30 COSM10667 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.646G>A p.V216M 7
31 COSM3733439 SMC1A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2398C>G p.Q800E 7
32 COSM3733438 SMC1A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2400G>T p.Q800H 7
33 COSM3733301 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2641G>A p.D881N 7
34 COSM3733382 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3109A>T p.N1037Y 7
35 COSM3733287 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.4600C>A p.Q1534K 7
36 COSM3733280 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3724G>T p.E1242* 7
37 COSM3733500 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3565C>G p.R1189G 7
38 COSM3733331 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2897G>A p.R966Q 7
39 COSM3733266 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3186C>G p.H1062Q 7
40 COSM3733321 SI haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1126C>T p.R376W 7
41 COSM3733285 SI haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1825T>C p.W609R 7
42 COSM3733430 SALL3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3044C>T p.S1015F 7
43 COSM3733372 ROBO2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2083C>T p.R695* 7
44 COSM3733347 ROBO2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.964G>A p.D322N 7
45 COSM3733293 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2570G>T p.R857L 7
46 COSM3733320 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.52G>A p.A18T 7
47 COSM3733492 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1535T>A p.L512* 7
48 COSM171725 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.838G>T p.E280* 7
49 COSM363436 POT1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.803G>A p.G268D 7
50 COSM3733311 POT1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.131G>A p.C44Y 7

Copy number variations for Mantle Cell Lymphoma from CNVD:

7 (show all 39)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 44978 10 6600000 12200000 Loss Mantle cell lymphoma
2 49103 11 102900000 110400000 Loss ACAT Mantle cell lymphoma
3 49104 11 102900000 110400000 Loss ATM Mantle cell lymphoma
4 49105 11 102900000 110400000 Loss CUL5 Mantle cell lymphoma
5 49106 11 102900000 110400000 Loss FDX1 Mantle cell lymphoma
6 49107 11 102900000 110400000 Loss NPAT Mantle cell lymphoma
7 49108 11 102900000 110400000 Loss RAB39 Mantle cell lymphoma
8 49703 11 110400000 112500000 Loss Mantle cell lymphoma
9 49990 11 112500000 114500000 Loss TMPRSS5 Mantle cell lymphoma
10 49991 11 112500000 114500000 Loss USP28 Mantle cell lymphoma
11 49992 11 112500000 114500000 Loss ZW10 Mantle cell lymphoma
12 54401 11 43500000 48800000 Loss TP53I11 Mantle cell lymphoma
13 60881 11 92800000 97200000 Loss MAML2 Mantle cell lymphoma
14 61262 11 97200000 102100000 Loss BIRC2 Mantle cell lymphoma
15 61263 11 97200000 102100000 Loss BIRC3 Mantle cell lymphoma
16 74176 13 101700000 104800000 Loss BIVM Mantle cell lymphoma
17 74177 13 101700000 104800000 Loss ERCC5 Mantle cell lymphoma
18 74178 13 101700000 104800000 Loss KDELC1 Mantle cell lymphoma
19 74694 13 110300000 115169878 Loss C13orf11 Mantle cell lymphoma
20 74695 13 110300000 115169878 Loss C13orf17 Mantle cell lymphoma
21 74696 13 110300000 115169878 Loss CUL4A Mantle cell lymphoma
22 74697 13 110300000 115169878 Loss GRTP1 Mantle cell lymphoma
23 74698 3 117011831 117647068 Loss LAMP Mantle cell lymphoma
24 74699 13 110300000 115169878 Loss TFDP1 Mantle cell lymphoma
25 77990 13 48877883 49056026 Deletion RB1 Mantle cell lymphoma
26 79883 13 79000000 95000000 Copy number miR-17-92 Mantle cell lymphoma
27 80925 13 99300000 101700000 Loss PCCA Mantle cell lymphoma
28 118115 17 7571720 7590868 Mutation P53 Mantle cell lymphoma
29 141432 2 210288771 210598834 Deletion MAP2 Mantle cell lymphoma
30 143512 2 237300000 243199373 Loss Mantle cell lymphoma
31 170852 3 160700000 167600000 Loss SLITRK3 Mantle cell lymphoma
32 245172 9 102600000 108200000 Loss INVS Mantle cell lymphoma
33 248837 9 137400000 141213431 Loss TRAF2 Mantle cell lymphoma
34 250734 9 21967751 21994490 Deletion CDKN2A Mantle cell lymphoma
35 252714 9 36300000 38400000 Loss MELK Mantle cell lymphoma
36 254747 9 68700000 72200000 Loss TJP2 Mantle cell lymphoma
37 256309 9 91800000 93900000 Loss DIRAS2 Mantle cell lymphoma
38 256992 9 99300000 102600000 Loss GPR51 Mantle cell lymphoma
39 256993 9 99300000 102600000 Loss TBC1D2 Mantle cell lymphoma

Expression for Mantle Cell Lymphoma

Search GEO for disease gene expression data for Mantle Cell Lymphoma.

Pathways for Mantle Cell Lymphoma

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 ATM BCL2 BTK CCND1 CCND2 CCND3
2
Show member pathways
13.49 BCL2 BTK CCND1 CCND2 CCND3 MDM2
3
Show member pathways
13.29 BCL2 BTK CCND1 CD19 MTOR MYC
4
Show member pathways
13.15 ATM BCL2 CCND1 CCND2 MDM2 MTOR
5
Show member pathways
13.04 ATM BCL6 MDM2 MTOR PMAIP1 TP53
6
Show member pathways
12.97 ATM BCL2 CCND1 CCND2 CCND3 CD19
7
Show member pathways
12.92 ATM BCL2 MCL1 MDM2 MYC PMAIP1
8 12.92 BCL2 CCND1 CCND2 CCND3 MDM2 MTOR
9
Show member pathways
12.83 BCL2 CCND1 MTOR MYC TP53
10
Show member pathways
12.8 BTK CD19 MDM2 MTOR TP53
11
Show member pathways
12.74 ATM CCND1 MDM2 MYC TP53
12
Show member pathways
12.68 ATM CCND1 CCND2 CCND3 MDM2 MYC
13
Show member pathways
12.67 BCL2 BCL6 CCND1 MTOR MYC
14
Show member pathways
12.65 BCL2 CCND1 MDM2 MTOR TP53
15
Show member pathways
12.65 BCL2 CCND1 MTOR MYC TP53
16
Show member pathways
12.63 CCND1 CCND2 CCND3 MYC TP53
17 12.62 ATM CCND1 CCND2 CCND3 MDM2 TP53
18
Show member pathways
12.57 BCL2 CCND1 CCND2 MTOR MYC
19
Show member pathways
12.56 CCND1 MDM2 MTOR MYC TP53
20
Show member pathways
12.55 MDM2 MTOR MYC TP53
21 12.54 ATM CCND1 CCND2 CCND3 MYC TP53
22
Show member pathways
12.53 ATM BCL2 MDM2 MTOR TP53
23 12.51 CCND1 CCND2 CCND3 MYC TP53
24 12.48 ATM CCND1 CCND2 CCND3 MDM2 MYC
25
Show member pathways
12.46 ATM CCND1 CCND2 CCND3 TP53
26
Show member pathways
12.45 BCL2 CCND1 CCND2 CCND3 MCL1 MTOR
27
Show member pathways
12.44 BCL6 BTK CD19 MYC
28
Show member pathways
12.44 CCND1 CCND2 CCND3 IGH MDM2 MTOR
29 12.41 CCND1 CCND2 CCND3 MDM2 PMAIP1 TP53
30 12.4 BCL2 CD19 MDM2 MYC TP53
31 12.4 CCND1 MDM2 MTOR MYC TP53
32
Show member pathways
12.4 ATM CCND1 CCND2 CCND3 MDM2 MYC
33
Show member pathways
12.38 BCL6 BTK CD19 MTOR
34
Show member pathways
12.36 ATM BCL2 CCND1 MDM2 TP53
35 12.35 ATM BCL6 BMI1 CCND2 MDM2 MYC
36 12.32 BCL2 MCL1 MYC PMAIP1
37
Show member pathways
12.29 CCND1 CCND2 CCND3 MYC
38
Show member pathways
12.28 BCL2 CCND1 CCND2 CCND3 MDM2 MTOR
39 12.26 CCND1 CCND2 MYC TP53
40
Show member pathways
12.26 CCND1 MDM2 MTOR MYC TP53
41 12.22 CCND1 CCND2 CCND3 MYC
42 12.21 ATM BCL2 CCND1 MDM2 MTOR MYC
43
Show member pathways
12.2 ATM BCL6 CCND1 CCND2 MDM2
44 12.19 BCL2 BCL6 MCL1 MDM2 PMAIP1 TP53
45 12.17 ATM CCND1 CCND2 CCND3 MDM2 MTOR
46 12.17 ATM BCL2 BMI1 CCND1 CCND2 EZH2
47
Show member pathways
12.15 BCL2 BTK CCND2 MYC
48 12.13 ATM BCL2 MDM2 TP53
49 12.11 CCND1 MDM2 MTOR MYC TP53
50 12.1 BCL2 BCL6 CCND1 MCL1 MYC TP53

GO Terms for Mantle Cell Lymphoma

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial outer membrane GO:0005741 9.62 BCL2 MCL1 MTOR PMAIP1
2 nucleoplasm GO:0005654 9.44 ATM BCL2 BCL6 BMI1 CCND1 CCND2
3 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.13 CCND1 CCND2 CCND3
4 cytoplasm GO:0005737 10.13 ATM BCL2 BMI1 BTK CCND1 CCND2
5 nucleus GO:0005634 10.06 ATM BCL2 BCL6 BMI1 BTK CCND1

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.98 BCL6 BTK CCND3 EZH2
2 negative regulation of gene expression GO:0010629 9.97 EZH2 MDM2 MYC SOX11
3 negative regulation of apoptotic process GO:0043066 9.95 BCL2 BCL6 CCND2 MCL1 MDM2 MYC
4 positive regulation of protein phosphorylation GO:0001934 9.94 CCND1 CCND2 CCND3 MTOR
5 cell cycle arrest GO:0007050 9.93 ATM MTOR MYC TP53
6 B cell receptor signaling pathway GO:0050853 9.89 BCL2 BTK CD19
7 regulation of gene expression GO:0010468 9.88 BCL2 BMI1 EZH2 MDM2 MYC
8 post-embryonic development GO:0009791 9.87 ATM BCL2 MTOR
9 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.85 ATM MDM2 TP53
10 regulation of apoptotic process GO:0042981 9.85 ATM BCL2 BCL6 MCL1 PMAIP1 TP53
11 response to cytokine GO:0034097 9.84 BCL2 MCL1 TP53
12 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.82 ATM BCL2 MCL1
13 negative regulation of autophagy GO:0010507 9.81 BCL2 MCL1 MTOR
14 cellular response to DNA damage stimulus GO:0006974 9.8 ATM BCL2 BCL6 CCND1 MYC PMAIP1
15 ovarian follicle development GO:0001541 9.79 ATM BCL2 MYC
16 cellular response to glucose starvation GO:0042149 9.79 BCL2 PMAIP1 TP53
17 cellular response to organic substance GO:0071310 9.78 BCL2 CCND1 MDM2
18 response to steroid hormone GO:0048545 9.77 BCL2 CCND1 MDM2
19 liver regeneration GO:0097421 9.77 CCND1 EZH2 MYC
20 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.75 BCL2 PMAIP1 TP53
21 response to gamma radiation GO:0010332 9.73 BCL2 MYC TP53
22 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.72 BCL2 PMAIP1 TP53
23 regulation of cell cycle GO:0051726 9.72 ATM BCL2 CCND1 CCND2 CCND3
24 determination of adult lifespan GO:0008340 9.71 ATM TP53
25 response to magnesium ion GO:0032026 9.71 CCND1 MDM2
26 cell aging GO:0007569 9.71 BCL2 MTOR TP53
27 growth GO:0040007 9.7 BCL2 MTOR
28 oocyte development GO:0048599 9.7 ATM BCL2
29 positive regulation of glial cell proliferation GO:0060252 9.7 MTOR MYC
30 cellular response to gamma radiation GO:0071480 9.7 ATM MDM2 TP53
31 response to UV-B GO:0010224 9.69 BCL2 TP53
32 positive regulation of DNA damage response, signal transduction by p53 class mediator GO:0043517 9.69 ATM PMAIP1
33 positive regulation of response to DNA damage stimulus GO:2001022 9.69 ATM MYC
34 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.69 CCND1 CCND2 CCND3
35 positive regulation of histone deacetylation GO:0031065 9.68 BCL6 TP53
36 cellular response to X-ray GO:0071481 9.68 ATM CCND2
37 mitotic G1 DNA damage checkpoint GO:0031571 9.68 CCND1 TP53
38 response to iron ion GO:0010039 9.67 BCL2 CCND1 MDM2
39 re-entry into mitotic cell cycle GO:0000320 9.65 CCND1 MYC
40 regulation of mitochondrial membrane permeability GO:0046902 9.63 BCL2 PMAIP1 TP53
41 positive regulation of neuron maturation GO:0014042 9.62 BCL2 MTOR
42 replicative senescence GO:0090399 9.61 ATM MME TP53
43 negative regulation of transcription by RNA polymerase II GO:0000122 9.61 BCL6 BMI1 CCND1 CCND3 EZH2 MDM2
44 cellular response to actinomycin D GO:0072717 9.57 MDM2 TP53
45 positive regulation of cell cycle GO:0045787 9.46 CCND1 MDM2 MYC TP53
46 cellular response to hypoxia GO:0071456 9.1 BCL2 MDM2 MTOR MYC PMAIP1 TP53
47 apoptotic process GO:0006915 10.14 ATM BCL2 BTK MCL1 PMAIP1 TP53
48 positive regulation of gene expression GO:0010628 10.06 MDM2 MTOR MYC SOX11 TP53
49 positive regulation of cell proliferation GO:0008284 10.06 BCL2 CCND1 CCND2 MDM2 MYC SOX11
50 cell proliferation GO:0008283 10.05 BCL2 CD5 MYC SOX11 TP53

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 ATM BCL2 BCL6 BMI1 BTK CCND1
2 protein kinase binding GO:0019901 9.55 CCND1 CCND2 CCND3 MTOR TP53
3 BH3 domain binding GO:0051434 8.96 BCL2 MCL1

Sources for Mantle Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....